Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
Allogeneic stem cell transplantation (SCT) from an HLA-haploidentical relative provides a potentially curative treatment option for hematologic malignancies patients who lack a suitably HLA-matched donor. The greatest challenge to performing HLA-haploidentical SCT has been high rates of graft failur...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2011-06-01
|
| Series: | Pediatric Reports |
| Online Access: | https://www.pagepress.org/journals/index.php/pr/article/view/2833 |
| _version_ | 1818453249701707776 |
|---|---|
| author | Ashley Munchel Chimen Kesserwan Heather J. Symons Leo Luznik Yvette L. Kasamon Richard J. Jones Ephraim J. Fuchs |
| author_facet | Ashley Munchel Chimen Kesserwan Heather J. Symons Leo Luznik Yvette L. Kasamon Richard J. Jones Ephraim J. Fuchs |
| author_sort | Ashley Munchel |
| collection | DOAJ |
| description | Allogeneic stem cell transplantation (SCT) from an HLA-haploidentical relative provides a potentially curative treatment option for hematologic malignancies patients who lack a suitably HLA-matched donor. The greatest challenge to performing HLA-haploidentical SCT has been high rates of graft failure and severe graft-versus-host disease (GVHD). Our group has been exploring high dose, post-transplantation cyclophosphamide (Cy) as prophylaxis of GVHD after nonmyeloablative, HLA-haploidentical bone marrow transplantation, or mini-haploBMT. Among 210 recipients of mini-haploBMT, 87% of patients have experienced sustained donor cell engraftment. The cumulative incidences of grades II-IV acute GVHD and chronic GVHD are 27% and 13%, respectively. Five-year cumulative incidence of non-relapse mortality is 18%, relapse is 55%, and actuarial overall survival and event-free survivals are 35% and 27%, respectively. These outcomes suggest that mini-haploBMT with post-transplantation Cy is associated with acceptably low toxicities and can provide longterm survival, if not cure, for many patients with advanced hematologic malignancies. |
| first_indexed | 2024-12-14T21:35:59Z |
| format | Article |
| id | doaj.art-63844e4d3d1742acba8ee8d340994309 |
| institution | Directory Open Access Journal |
| issn | 2036-749X 2036-7503 |
| language | English |
| last_indexed | 2024-12-14T21:35:59Z |
| publishDate | 2011-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pediatric Reports |
| spelling | doaj.art-63844e4d3d1742acba8ee8d3409943092022-12-21T22:46:35ZengMDPI AGPediatric Reports2036-749X2036-75032011-06-01e15e1510.4081/pr.2011.s2.e152833Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamideAshley Munchel0Chimen KesserwanHeather J. SymonsLeo LuznikYvette L. KasamonRichard J. JonesEphraim J. FuchsPAGEPress Office, PaviaAllogeneic stem cell transplantation (SCT) from an HLA-haploidentical relative provides a potentially curative treatment option for hematologic malignancies patients who lack a suitably HLA-matched donor. The greatest challenge to performing HLA-haploidentical SCT has been high rates of graft failure and severe graft-versus-host disease (GVHD). Our group has been exploring high dose, post-transplantation cyclophosphamide (Cy) as prophylaxis of GVHD after nonmyeloablative, HLA-haploidentical bone marrow transplantation, or mini-haploBMT. Among 210 recipients of mini-haploBMT, 87% of patients have experienced sustained donor cell engraftment. The cumulative incidences of grades II-IV acute GVHD and chronic GVHD are 27% and 13%, respectively. Five-year cumulative incidence of non-relapse mortality is 18%, relapse is 55%, and actuarial overall survival and event-free survivals are 35% and 27%, respectively. These outcomes suggest that mini-haploBMT with post-transplantation Cy is associated with acceptably low toxicities and can provide longterm survival, if not cure, for many patients with advanced hematologic malignancies.https://www.pagepress.org/journals/index.php/pr/article/view/2833 |
| spellingShingle | Ashley Munchel Chimen Kesserwan Heather J. Symons Leo Luznik Yvette L. Kasamon Richard J. Jones Ephraim J. Fuchs Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide Pediatric Reports |
| title | Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide |
| title_full | Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide |
| title_fullStr | Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide |
| title_full_unstemmed | Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide |
| title_short | Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide |
| title_sort | nonmyeloablative hla haploidentical bone marrow transplantation with high dose post transplantation cyclophosphamide |
| url | https://www.pagepress.org/journals/index.php/pr/article/view/2833 |
| work_keys_str_mv | AT ashleymunchel nonmyeloablativehlahaploidenticalbonemarrowtransplantationwithhighdoseposttransplantationcyclophosphamide AT chimenkesserwan nonmyeloablativehlahaploidenticalbonemarrowtransplantationwithhighdoseposttransplantationcyclophosphamide AT heatherjsymons nonmyeloablativehlahaploidenticalbonemarrowtransplantationwithhighdoseposttransplantationcyclophosphamide AT leoluznik nonmyeloablativehlahaploidenticalbonemarrowtransplantationwithhighdoseposttransplantationcyclophosphamide AT yvettelkasamon nonmyeloablativehlahaploidenticalbonemarrowtransplantationwithhighdoseposttransplantationcyclophosphamide AT richardjjones nonmyeloablativehlahaploidenticalbonemarrowtransplantationwithhighdoseposttransplantationcyclophosphamide AT ephraimjfuchs nonmyeloablativehlahaploidenticalbonemarrowtransplantationwithhighdoseposttransplantationcyclophosphamide |